findmyKOL

John Belperio, MD

Enriched profile

Professor of Medicine; Division Chief, Pulmonary, Critical Care & Sleep Medicine, David Geffen School of Medicine at UCLA · University of California, Los Angeles

ORCIDNPI
Region🇺🇸 Los Angeles, CA · West · United StatesSpecialtyPulmonary DiseaseFocusIdiopathic Pulmonary Fibrosis
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2001–2026

John Belperio is Professor of Medicine; Division Chief, Pulmonary, Critical Care & Sleep Medicine, David Geffen School of Medicine at UCLA at University of California, Los Angeles. OpenAlex indexes 571 publications with 21,088 citations (h-index 77); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.

Data verified 17 Aug 2026

Overview

Updated 27 Aug 2026

John Belperio, MD, is Professor of Medicine at University of California, Los Angeles (David Geffen School of Medicine). The public record shows 571 publications with 21,088 citations (h-index 77), centered on Idiopathic Pulmonary Fibrosis. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 10 companies, 7 NIH-funded awards (2001–2026).

  • Most recent indexed publication: 2026 · bioRxiv
  • Top research focus: Idiopathic Pulmonary Fibrosis
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Idiopathic Pulmonary Fibrosis3 trialsLung Diseases, Interstitial1 trialInflammation1 trial

Research focus

OpenAlex concept fingerprint
Idiopathic Pulmonary Fibrosis

Drugs & molecules

across trials, industry payments and publications
Ofevgeneric · NintedanibClinical trialsIndustry payments31PublicationsEsbrietgeneric · PirfenidoneClinical trialsIndustry payments3PublicationsBerinertgeneric · C1 esterase inhibitorClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trialsIndustry payments74Duke UniversityClinical trials3Industry paymentsGenentech, Inc.Clinical trialsIndustry payments3

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
571publications

Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.

21,088citations

Total citations across indexed works.

77h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials
10companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
7NIH grants · 2001–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    40.3%
    Corticosteroid36.7%
    Trelegy Ellipta52%Breo Ellipta18%Breztri Aerosphere18%Fluticasone Propionate8%Arnuity Ellipta5%
    Part D<11 patients
    beta2-Adrenergic Agonist2.4%
    Albuterol Sulfate Hfa100%
    Part D11 patients
  • Anti-infectives

    29.7%
    Tetracycline-class Drug9.7%
    Doxycycline Hyclate100%
    Part D52 patients
    Macrolide Antimicrobial8%
    Azithromycin100%
    Part D51 patients
  • Metabolism & gastrointestinal

    18.6%
    Corticosteroid14.5%
    Prednisone100%
    Part D65 patients
    Proton pump inhibitor4.1%
    Pantoprazole Sodium63%Esomeprazole Magnesium37%
    Part D<11 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)79.8% facility · 20.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

7 NIH research awards on record, funded 20012026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/john-belperio-0688077

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/scientific-contributions/John-A-Belperio-38860565

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • ResearchGate

    researchgate.net/scientific-contributions/John-Belperio-2238415501

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
1 more verified account behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/p/DHZBY57y83m

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com
  • LinkedIn

    linkedin.com/posts/ucla-health_dr-john-belperio-awarded-2024-ucla-younes-activity-7288005041632821248-pwFU

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    newsroom.ucla.edu/experts/john-belperio

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newsroom.ucla.edu
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Pulmonary Disease, American Board of Internal Medicine

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org
  • Board Certified

    Critical Care Medicine, American Board of Internal Medicine

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org
  • Board Certified

    Internal Medicine, American Board of Internal Medicine

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org
  • MD

    Temple University School of Medicine

    1994
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org

Editorial & leadership roles

journal and society appointments
  • Division Chief

    Pulmonary, Critical Care & Sleep Medicine, UCLA Health

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org
  • Principal Investigator

    Belperio Lab, David Geffen School of Medicine at UCLA (research on lung transplantation, chronic lung allograft dysfunction, idiopathic pulmonary fibrosis, chemokine biology)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →belperiolab.dgsom.ucla.edu

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Member

    Cancer and Stem Cell Biology Program, UCLA Jonsson Comprehensive Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org

Media & interviews

press, podcasts and appearances
  • Guest

    "Sarc Fighter: Living with Sarcoidosis and other rare diseases" podcast, Episode 78 (Jan 2, 2023), discussing state of sarcoidosis research

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →beatsarc.podbean.com

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.